1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
DyDo Pharma Files Its 1st Drug, LEMS Treatment for Japan Market
Japanese beverage manufacturer DyDo Group Holdings said on December 18 that its subsidiary DyDo Pharma made a Japan submission for a Lambert-Eaton myasthenic syndrome (LEMS) treatment. This marks the first new drug application filed by DyDo Pharma. The application was…
To read the full story
Related Article
BUSINESS
- Nxera Assigns Cenerimod Rights in Japan, APAC to Viatris
March 3, 2025
- Ono to Consolidate US, European Operations to Deciphera
March 3, 2025
- Over 60% of Doctors Have Prejudices about Obesity: Lilly/Mitsubishi Survey
March 3, 2025
- GSK Vows to Ensure Proper Use of Shingles Jab towards NIP Inclusion
March 3, 2025
- Eisai Licenses Tasfygo to SciClone in Greater China Region
March 3, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…